The global Liver Cancer Diagnostics market size is expected to hit around US$ 20.4 billion by 2030, according to a new report by Vision Research Reports.
The global Liver Cancer Diagnostics market size is expected to hit around US$ 20.4 billion by 2030, according to a new report by Vision Research Reports.
The global Liver Cancer Diagnostics market size was valued at US$ 10.7 billion in 2020 and is anticipated to grow at a CAGR of 8.5% during forecast period 2021 to 2030.
Report Highlights
- The laboratory tests segment dominated the market for liver cancer diagnostics and accounted for the largest revenue share of 39.5%.
- The hospitals and diagnostic laboratories segment dominated the market for liver cancer diagnostics in 2020 and accounted for the largest revenue share of 83.4%.
- North America dominated the liver cancer diagnostics market and accounted for the largest revenue share of 40.1% in 2020 and is projected to remain dominant throughout the forecast period.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38898
Growth Factors
rise in the number of programs to raise awareness about early diagnosis of liver cancer is also expected to be a key factor responsible for increasing the demand for its diagnostic products worldwide. The major risk factors for this disease include chronic viral hepatitis, Cirrhosis, heavy alcohol consumption, tobacco consumption, and obesity. Early screening and diagnosis of liver cancer is the core stone for the control of related mortality, thus, creates a high demand for innovative diagnostics tests. Liver cancer is one of the leading causes of cancer-related deaths around the world. According to the American Cancer Society, in the past few decades, the incidence rates of liver cancer have more than tripled and the death rates have more than doubled during this time.
Report Coverage
Report Scope | Details |
Market Size | US$ 20.4 Billion by 2030 |
Growth Rate | CAGR of 8.5% From 2021 to 2030 |
Base Year | 2021 |
Forecast Period | 2021 to 2030 |
Segments Covered | Test type, End use |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Mentioned | Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Qiagen N.V.; Thermo Fisher Scientific, Inc.; Siemens Healthineers; Becton Dickinson & Company; Illumina, Inc.; Koninklijke Philips N.V; Epigenomics AG; Fujifilm Medical Systems U.S.A., Inc. |
Market Dynamics
- By test type, the laboratory tests segment emerged as the largest segment in 2020 owing to its increased demand for effective diagnosis of hepatocellular carcinoma
- Based on end use, the hospitals and diagnostic laboratories segment accounted for the leading revenue share during the forecast period, as they are the primary centers for the diagnosis and treatment of all chronic diseases
- North America dominated the market and accounted for the largest revenue share in 2020. The improved awareness about hepatocellular carcinoma and high adoption of novel technologies are facilitating the dominance of this region during the forecast period
- In Asia Pacific, the market is estimated to show the fastest growth during the study period. This high growth can be attributed to the presence of a huge target population and developing healthcare infrastructure in emerging countries
By Test Type Analysis
the laboratory tests segment dominated the market for liver cancer diagnostics and accounted for the largest revenue share of 39.5%. The segment is projected to grow at the fastest rate during the forecast period. This large share and growth can be attributed to the high preference for laboratory tests due to their accuracy and cost-efficiency.
The imaging tests segment accounted for the second-largest revenue share and is anticipated to show significant growth throughout the study period. Imaging tests can be supportive tests for laboratory and genetic tests that help confirm the presence of a tumor. Imaging tests include Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI) scan, X-ray, ultrasound, and other radiographic tests.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38898
By End-use Analysis
The hospitals and diagnostic laboratories segment dominated the market for liver cancer diagnostics in 2020 and accounted for the largest revenue share of 83.4%. Hospitals are primary care settings for the diagnosis and treatment of medical conditions including hepatocellular carcinoma.
The pharmaceutical and CRO laboratories segment is anticipated to witness the fastest CAGR during the forecast period. This high growth can be attributed to the high demand for liver diagnostics solutions by leading pharmaceutical companies for research purposes.
By Regional Analysis
North America dominated the liver cancer diagnostics market and accounted for the largest revenue share of 40.1% in 2020 and is projected to remain dominant throughout the forecast period.
In Asia Pacific, the market for liver cancer diagnostics is expected to exhibit the highest growth throughout the study period. This high growth can be attributed to the high prevalence of Hepatitis in emerging countries including India and China.
Key Players
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Siemens Healthineers
- Becton Dickinson & Company
- Illumina, Inc.
- Koninklijke Philips N.V.
- Epigenomics AG
- Fujifilm Medical Systems U.S.A., Inc.
Market Segmentation
- By Test Type
- Laboratory Tests
- Biomarkers
- Oncofetal and Glycoprotein Antigens
- Enzymes and Isoenzymes
- Growth Factors and Receptors
- Molecular Markers
- Pathological Biomarkers
- Blood Tests
- Biomarkers
- Imaging Tests
- Endoscopy
- Biopsy
- Others
- Laboratory Tests
- By End-use
- Hospitals & Diagnostic Laboratories
- Academic & Research Institutes
- Pharmaceutical & CRO Laboratories
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38898
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/